The Safety of Peanut Oral Immunotherapy in Peanut-Allergic Subjects in a Single-Center Trial

Publisher： Karger

E-ISSN： 1423-0097|159|2|179-182

ISSN： 1018-2438

Source： International Archives of Allergy and Immunology, Vol.159, Iss.2, 2012-06, pp. : 179-182

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Analysis of cytokine production by peanut‐reactive T cells identifies residual Th2 effectors in highly allergic children who received peanut oral immunotherapy

By  

CLINICAL & EXPERIMENTAL ALLERGY, Vol. 45, Iss. 7, 2015-07 ,pp. : 1201-1213

John Wiley & Sons Inc

Access to resources Recommend Favorite

Modulation of Peanut‐specific humoral and cellular responses pre‐ and post‐oral immunotherapy

By  

CLINICAL & EXPERIMENTAL ALLERGY, Vol. 45, Iss. 7, 2015-07 ,pp. : 1146-1149

John Wiley & Sons Inc

Access to resources Recommend Favorite

The longitudinal impact of probiotic and peanut oral immunotherapy on health‐related quality of life

By  

ALLERGY, Vol. 73, Iss. 3, 2018-03 ,pp. : 560-568

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prolonged Treatment of Peanut-Allergic Mice with Bortezomib Significantly Reduces Serum Anti-Peanut IgE but Does Not Affect Allergic Symptoms

By  

International Archives of Allergy and Immunology, Vol. 170, Iss. 4, 2016-10 ,pp. : 257-261

Karger

Access to resources Recommend Favorite

A Single Oral Sensitization to Peanut without Adjuvant Leads to Anaphylaxis in Mice

By  

International Archives of Allergy and Immunology, Vol. 146, Iss. 3, 2008-02 ,pp. : 212-218

Karger

Access to resources Recommend Favorite